Trial Profile
Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Endoxifen (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Fibroma; Gynaecological cancer; HER2 positive breast cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Uterine cancer
- Focus Adverse reactions
- 13 Jun 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 15 Jun 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.
- 17 Sep 2021 Results (n=80) assessing the population pharmacokinetics (PK) of Z-endoxifen in patients with treatment-refractory gynecologic malignancies, desmoid tumors or hormone receptor-positive solid tumors from Mayo Clinic (NCT01327781) and National Cancer Inst (NCI, NCT01273168) trials, presented at the 2021 American College of Clinical Pharmacology Annual Meeting.